University of Hawaii Cancer Center and Queen's to collaborate on oncology clinic
1 /3 COURTESY UH CANCER CENTER The Queen's Health Systems and University of Hawaii Cancer Center will develop an oncology clinic at the UH John A. Burns School of Medicine in Kakaako.
COURTESY PHOTO Naoto Ueno 2 /3 COURTESY PHOTO Naoto Ueno COURTESY PHOTO Darlena Chadwick 3 /3 COURTESY PHOTO Darlena Chadwick COURTESY UH CANCER CENTER The Queen's Health Systems and University of Hawaii Cancer Center will develop an oncology clinic at the UH John A. Burns School of Medicine in Kakaako.
COURTESY PHOTO Naoto Ueno COURTESY PHOTO Darlena Chadwick The University of Hawaii Cancer Center and The Queen's Health Systems are teaming up to provide cutting-edge, comprehensive cancer care to residents under one roof.
The two institutions signed a memorandum of understanding to jointly develop oncology clinic space at the Cancer Center's facilities at the UH John A. Burns School of Medicine campus in Kakaako.
'As a member of the Hawaii Cancer Consortium, The Queen's Health Systems has always been one of the state's most powerful allies in the fight against cancer, ' said UH Cancer Center Director Dr. Naoto Ueno in a statement. 'This agreement builds on our mutually beneficial collaboration as we continue to save lives, and help ensure patients in Hawaii and the U.S-affiliated Pacific Islands can continue to benefit from cancer research that yields better preventive care, earlier detection of different types of cancer among different ethnicities, and improved treatment options for cancer patients.'
Queen's will lease and build out the third and fourth floors of the center's Ewa wing to offer medical oncology, surgical oncology and chemotherapy infusion services.
UH has already been building out the first and second floors for Hawaii's first early-phase clinical research center. Construction of, which means healing, is expected to be done by the end of the year.
Ueno said the collaboration will offer Hawaii patients the best standard of multidisciplinary care along with access to early-phase clinical trials without having to fly out of state, which is the center's goal.
Don 't miss out on what 's happening !
Stay in touch with breaking news, as it happens, conveniently in your email inbox. It 's FREE !
Email 28141 Sign Up By clicking to sign up, you agree to Star-Advertiser 's and Google 's and. This form is protected by reCAPTCHA.
'We have a lot of good clinicians here and we really want to have this sense that everybody can stay on the island, ' he said. 'You don't have to go to the continent—that's the ultimate goal. We want to save lives in Hawaii and the Pacific.'
Darlena Chadwick, executive vice president and chief operating officer of The Queen's Health Systems, said the move into the UH Cancer Center will expand services in high demand.
'We were really looking at how we serve our community and our patients better, and having everything in that location would be ideal for our patients, ' Chadwick said. 'They could see their medical oncologist, their surgical oncologist, they could get their infusion treatment, and then if they're enrolled in a clinical trial or an early phase trial, they can go right downstairs.'
Cancer care services will still be available at individual Queen's campuses, she said, but the additional clinic at the UH Cancer Center will help minimize the time between diagnosis to treatment for patients, particularly with numerous wait lists.
Queen's is also expanding its cancer program in West Oahu to accommodate more patients.
In Hawaii, an average of about 7, 400 residents are diagnosed with invasive cancer yearly and about 2, 400 die from cancer every year. Hawaii is home to more than 65, 000 cancer survivors.
Among women, breast cancer remains the most frequently diagnosed cancer in Hawaii. Among men, prostate is the most common cancer. Lung cancer is still the leading cause of cancer deaths among both men and women.
Last fall, the UH Cancer Center renewed its from the National Cancer Institute, maintaining its position among the top 4 % of cancer centers in the U.S.
The designation reflects the center's ongoing commitment to rigorous state-of-the-art research, along with care standards focusing on Hawaii's uniquely diverse population, including Native Hawaiians, Pacific Islanders and Filipinos.
Ho 'ola is a collaborative project with the Hawai 'i Cancer Consortium, which includes partners such as Queen's and Hawaii Pacific Health. The consortium will work with University Health Partners of Hawaii to make early-phase clinical trial treatments available to residents.
Queen's does not yet have an estimated cost of construction or timeline for when its UH Cancer Center clinics will be completed, but it will be several years out.
The Queen's Medical Center has been accredited by the American College of Surgeons Commission on Cancer, meaning patients have access to comprehensive care, including a range of state-of-the-art services and equipment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
2 hours ago
- Wall Street Journal
Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time
Thousands of Medicare recipients will have to wait longer to get some price relief on the expensive cancer drugs they depend on for treatment, while others might not get any reprieve at all. Two little-known provisions in the One Big Beautiful Bill Act signed by President Trump in July will delay Medicare price negotiations for some of the biggest-selling drugs in the world, including Merck's Keytruda, which is used to treat cancer and had $17.9 billion in U.S. sales in 2024. Other drugs, such as Johnson & Johnson's Darzalex, will be excluded entirely.
Yahoo
2 days ago
- Yahoo
No city is safe for allergy sufferers, study finds
There's no escape from it — pollen is in every U.S. state, ready to torment your nostrils. The seeds rain down from the trees in a strange yellow haze and ascends to the skies from the flowers and grasses. Even if you could easily pack up and move, nowhere is safe to avoid the dreaded, sniffling effects of seasonal allergies. 'It's a little bit like playing Russian Roulette,' Hannah Jaffee, the director of research at the Asthma and Allergy Foundation of America, told The Independent. 'If you already have allergies, you can be exposed to an entirely different set of allergens if you relocate.' 'Worst case scenario: you may live in a place and either not have allergy symptoms or have mild allergy symptoms. Then, you move somewhere else and start developing significant symptoms,' she added. Everyone is going to respond differently to a new location. 'If you already have allergies, you can be exposed to an entirely different set of allergens if you relocate. So, you might be trading some symptoms for others.' 'And then, in some cases, your symptoms might improve by relocating,' Jaffee said. More than 100 million Americans live with various types of allergies and over 81 million have seasonal pollen allergies. Some are genetically predisposed to develop allergies, which can factor into what they're allergic to and potentially how severe their symptoms would be. Many people develop allergies as they age and their immune system weakens. Seasonal allergies, which are also commonly known as 'allergic rhinitis' or hay fever, occur when people are exposed to pollen. The inflammatory response can cause sneezing, congestion, a runny nose, or red, watery, and itchy eyes. For people with asthma, it can lead to an asthma attack. For tens of thousands of people, it may even result in a trip to the emergency room. The severity of allergy symptoms also depends on where you live. There are three main types of pollen, including tree, grass, and weed. This year, the highest tree pollen levels were forecast across a wide swath stretching from the Pacific Northwest to the Southeast. The highest weed pollen levels were expected around the Plains states, the Carolinas, and along the Gulf Coast. The foundation also released what it named the nation's top 10 cities for seasonal allergies, with most located in the South and Southeast. Historically, the worst cities are in those regions, Jaffee noted. 'That's because these are climates that tend to be more humid and warmer, so they kind of favor that growth of pollen and mold,' she explained. Wichita, Kansas, led the rankings as the worst city for allergy sufferers. 'Since allergies are so different for everyone, you can thrive in the Southeast part of the U.S. and not have any allergies or still experience significant allergy symptoms elsewhere,' Jaffee said. 'It's kind of a mixed bag.' So, what do you do if you are moving — or want to? Generally, experts recommend that you visit the location for about two to four weeks ahead of time to get a sense of how your body responds, or to visit during different seasons. Talking to an allergist will also be useful for more personalized recommendations. Still, pollen seasons are getting longer and stronger for everyone. Human-caused climate change is resulting in earlier seasons, as well, with warmer temperature trapping heat around urban areas, increasing air pollution, and stimulating pollen production. The amount of pollen released by trees is higher and the strength of the allergic response to the tree pollen appears to be stronger. 'There's no question [that] as there's global warming, the pollen season is increasing,' Dr, Sanjiv Sur, director and professor of Allergy and Immunology at Baylor College of Medicine, said earlier this year. What may help ease the pain, if only for right now? Dr. Neelu Tummala, a clinical assistant professor of otolaryngology at NYU Langone Health, advises that people time taking medications so they are optimally effective, change clothes and take off shoes after spending time outside, and bathe pets. Jaffee recommends a pollen tracking app, in addition to personalized allergy testing. But, ultimately, there needs to be a wider response. 'Long-term, we should be looking at policy change to reduce the impact of climate change,' said the foundation's chief mission officer Melanie Carver. Solve the daily Crossword
Business Insider
2 days ago
- Business Insider
M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics
U.S.-based AbbVie Inc. (ABBV) is reportedly in discussions to buy clinical-stage biotech company Gilgamesh Pharmaceuticals. According to sources familiar with the matter, the deal could be valued at around $1 billion for Gilgamesh. While talks are ongoing, an official announcement might come in the next few weeks. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AbbVie develops innovative therapies for complex health conditions. Meanwhile, Gilgamesh is a clinical-stage biotech firm working on treatments for psychiatric conditions such as depression, anxiety, and PTSD. AbbVie Turns to M&A for Future Growth The potential deal would bolster AbbVie's pipeline of potential treatments for psychiatric disorders. Notably, Gilgamesh is developing neuroplastogens, a type of next-generation psychedelic compound. Notably, AbbVie continues expanding into mental health treatments after its blockbuster arthritis drug Humira lost U.S. patent protection in 2023, triggering a sales decline. The company now focuses on expanding its drug portfolio, supported by newer therapies and smart acquisitions. According to Reuters, the company has spent more than $20 billion on acquisitions since 2023 to offset its declining sales. Furthermore, the acquisition buzz comes more than a year after AbbVie and Gilgamesh entered into an option-to-license agreement to develop novel therapies for psychiatric disorders. As part of this partnership, AbbVie and Gilgamesh will jointly research and develop next-generation treatments for psychiatric disorders. Separately, the company will release its second-quarter results for 2025 on Thursday, July 31. Analysts on Wall Street expect AbbVie to post earnings of $2.88 per share in its upcoming quarterly report, up from $2.65 reported in the same period last year. Is AbbVie a Good Stock for 2025? On TipRanks, ABBV stock has a consensus Moderate Buy rating among 15 Wall Street analysts. That rating is based on nine Buys and six Holds assigned in the last three months. The average AbbVie stock price target of $209.33 implies an 11% upside from current levels.
